MENU

ARWR Stock Tickeron detected bullish Stock Pattern: Cup-and-Handle ARWR on April 22, 2025, netting in a 24.29% gain over 3 weeks

A.I.dvisor
at Tickeron.com
Loading...
+24.29% Gain from a Successful pattern Cup-and-Handle
ARWR - Arrowhead Pharmaceuticals
Tickeron
Ticker: ARWR
Company: Arrowhead Pharmaceuticals
Gain: +24.29%
Confirmed: 04/22/25
Succeeded: 05/12/25
Total length: 25 days
On April 17, 2025, A.I.dvisor detected a Cup-and-Handle Pattern (Bullish) for Arrowhead Pharmaceuticals (ARWR, $11.24). On April 22, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $15.57. 20 days later, on May 12, 2025, ARWR reached the target price resulting in a +2 for traders who took a long position in the stock.

ARWR in +17.27% Uptrend, growing for three consecutive days on May 13, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARWR advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where ARWR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 12, 2025. You may want to consider a long position or call options on ARWR as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARWR just turned positive on April 14, 2025. Looking at past instances where ARWR's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

ARWR moved above its 50-day moving average on May 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARWR crossed bullishly above the 50-day moving average on May 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 181 cases where ARWR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARWR broke above its upper Bollinger Band on May 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARWR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.496) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (714.286) is also within normal values, averaging (254.920).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
177 E. Colorado Boulevard
Phone
+1 626 304-3400
Employees
525
Web
https://www.arrowheadpharma.com